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What is genomic instability and why is it so common in cancer? 
 
Genomic instability describes a state in which there is an increased tendency to acquire 
hereditable genetic alterations that may influence phenotype. It characteristically occurs as 
a consequence of deficient genome maintenance processes, such as DNA repair or cell-cycle 
checkpoints [1].  The genetic alterations that arise are often typified, both in terms of the 
mechanism of their formation and their functional consequences, by their size. At the 
smallest scale, the bases at individual nucleotides may be substituted. At the largest scale, 
entire chromosomes may be gained and lost. Cancers cells often harbour several types of 
genomic alteration that span the wide range of these limits [2] (Table 1). 
 
Table 1 – Genetic alterations come in different shapes and sizes 
 
Genetic Alteration Description Example(s) of causative 
genomic instability 
Single Nucleotide Variant (SNV) The substitution of the 
base at an individual 
nucleotide. 
POLE proofreading mutation 
[3]  
Insertion/Deletion (Indel) The gain or loss, 
respectively, of one or a 
few nucleotides. 
BRCA1/BRCA2 deficiency [4] 
Copy Number Variant (CNV) The gain or loss of copies 
of a segment of DNA, 
such as a gene. 
Aurora A amplification [5] 
Transposon activity [6] 
Translocation The rearrangement of 
non-homologous 
chromosomes. 
BRCA1/BRCA2 deficiency [4] 
AID/APOBEC activity [7]  
Aneuploidy The gain or loss of entire 
chromosomes 
p53 deficiency [8] 
 
The 2011 update detailing the Hallmarks of Cancer identified genomic instability as an 
enabling characteristic of cancer [9]. In principle, the acquisition of genomic instability 
facilitates carcinogenesis by enabling a cell and its descendants to alter their genomes. As 
each cell in this lineage acquires new genetic alterations, a group of cells that are genetically 
heterogeneous is formed. This sets the stage for the selection of cells that have acquired a 
growth advantage. Mutations emerge that enable cells to break free of homeostatic limits 
such as those involving proliferation, invasion, evading cell death et cetera, leading to 
classical cancerous behaviour. 
 
Defining genomic instability as an enabling characteristic predicates that it must also occur 
early during tumourigenesis. In keeping with this notion, it is notable that disruption of p53, 
a protein notorious for its capacity to restrict several types of genomic instability, is the 
most common founder event in cancer [8, 10]. It is also of note that a large proportion of 
cancer predisposition syndromes are attributable to defects in genes involved genome 
maintenance, and that carcinogenesis occurs precociously in affected individuals (reviewed 
in [11]). These findings are consistent with next-generation sequencing (NGS) data which 
consistently identify patterns of genomic instability at early stages of cancer development 
[12, 13].  
These NGS approaches allow us to distinguish between ongoing genomic instability, and the 
‘scars’ of past episodes of genomic instability that may be detected by sequencing. Thus, 
technically, genomic instability defines the rate of mutation whereas the readout from NGS 
generally provides a static snapshot of its impact. However, comparative sequencing of 
serially acquired or spatially distinct samples can provide a better reflection of mutational 
rates. In sum, these studies have confirmed that practically all cancers carry several 
mutations in their genome, although the burden of mutations varies across tumour types. In 
most solid tumours, on average 33 to 66 genes are significantly mutated, whilst in lung 
cancer and melanoma this number is nearer 200 [14].  
 
The causes and consequences of genomic instability are diverse 
 
Although the rationale for genomic instability can be explained relatively simply, its causes 
and consequences are far more nuanced. As described earlier – mutational burden, and by 
inference genomic instability, varies across different tumour types.  In addition, beyond 
number of mutations, genomic instability can also differ based on the type of mutations 
present. Indeed, various mutational signatures have been deconvoluted from mixed 
patterns of SNVs in cancer genomes. In 2013, a seminal paper identified 21 distinct 
mutational signatures on the basis of 4,938,362 mutations from 7,042 cancers [15]. Certain 
signatures were associated with known mechanisms of mutagenesis. For instance, Signature 
7 was frequently seen in malignant melanoma and was attributed to DNA damage from 
ultraviolet light. A smoking-related signature was also reported in lung cancer.   
 
Further signatures were connected to with DNA repair defects. Within the cell, damaged 
DNA is repaired through multiple processes and the choice of repair pathway is 
characteristically associated with the type of DNA lesion. For instance, mismatch repair 
(MMR) acts on base-base mismatches and insertion/deletion mispairs, whereas homologous 
recombination (HR) repairs breaks in double-strand DNA. Defects in MMR (e.g. through 
MLH1 inactivation) and HR (e.g. through BRCA1 and BRCA2 inactivation) are classically 
associated with colorectal cancers or breast and ovarian cancers, respectively. However the 
reasons behind these tissue specificities have proven far harder to decipher. They may 
partly be explained by the fact that genes are expressed differentially across tissue types 
and that each site has a unique microenvironment and exposure to exogenous agents. For 
instance BRCA1 has been shown to mediate early differentiation of breast tissue and has 
also been implicated in the repair of double-stranded DNA breaks from estrogen and 
estrogen metabolites [4, 16, 17].  
 
Together, these findings only reveal a limited view of the true sequence of events but 
reiterate that multiple mechanisms are likely to be involved. In fact, it has also become 
apparent that genomic instability does not continue at a steady and unrelenting rate 
throughout tumour evolution [13]. This is important because such complexity amplifies 
manifold the challenge of translating our scientific understanding into improvements to 
clinical care. Indeed, as yet there are no reliable clinical biomarkers for genomic instability 
and this is in large-part due to its temporal dynamics (reviewed in [18]). This is because, as 
already discussed, current techniques used to measure features associated with genomic 
instability, e.g. aneuploidy, provide static snapshots which do not robustly correlate with 
the true nature of instability present.       
 
How does the science of genomic instability translate into better patient outcomes? 
 
Cancer prevention and early diagnosis 
 
Identifying individuals who are predisposed to cancer due to inherited changes in genome 
maintenance processes is of significant clinical value. This is because these patients can then 
be targeted for cancer prevention strategies and/or screened in order to diagnose cancers 
at an early and potentially curable stage. In this cohort of patients one could hypothesise 
that relatively simple interventions such as smoking cessation could have profound effects 
on cancer risk reduction. If we were better able to understand the mechanisms behind 
cancer predisposition in these men and women more specific interventions could also be 
developed.   
 
These principles are already being applied in the management of individuals carrying 
germline mutations in the BRCA1 or BRCA2 gene. Cancer predisposition in these cases is 
associated with increased genomic instability (reviewed in [4]). These individuals may 
benefit from cancer detection and prevention strategies. Women with BRCA1 and BRCA2 
mutations are currently offered the choice between more intensive screening or bilateral 
mastectomy and oophorectomy. Recent clinical evidence also supports the use of tamoxifen 
in these cases as a cancer prevention strategy. A pooled observational cohort study of 
almost 1600 BRCA mutation carriers showed that tamoxifen use following a diagnosis of 
breast cancer reduced the risk of cancer by around a half in the contralateral breast [19].  
 
Cancer treatment  
 
One can argue that the genomic instability of cancer has long been a target of cancer 
therapy, based on the relative sensitivity of cancer cells to cytotoxic drugs and radiotherapy 
when compared to normal tissue. This notion is exemplified by the effectiveness of PARP 
inhibitors in BRCA deficient cells. This, alongside other advances in using DNA repair 
inhibitors for cancer treatment is reviewed elsewhere [20, 21]. Our review focuses on the 
implications of genomic instability as a whole on anticancer therapy. 
 
How may we appraise the impact that genomic instability has upon cancer therapy? A study 
aimed at addressing this question used sequencing data from a broad range of tumour types 
and associated CNVs with clinical outcome. The results showed that tumours with either the 
lowest or highest rate of CNVs carried the most favourable outcomes [22]. This suggests 
that either too little or too much genomic instability can be detrimental to a cancer’s 
survival. There are a number of possible explanations for these intriguing findings. Cancers 
require a minimum level of instability so that they are more easily able to evolve resistance 
mechanisms to the therapeutic agent. Whilst in those cancers with high levels of instability 
(>75% CNVs), genome maintenance is impaired to the extent that the chances of producing 
viable daughter cells is significantly lowered. Moreover, these cells may be exquisitely 
sensitive to DNA damaging agents due to massively impaired DNA repair, and may also be 
more susceptible to destruction by the immune system (discussed later). These results 
suggest that we can stratify patients based on their profiles of genomic instability. However, 
as already discussed, an accurate biomarker of genomic instability remains to be discovered.  
 
In 2017, the TracerX study published preliminary data from 100 lung cancer patients who 
had multiple spatially distinct surgical samples sent for sequencing [23]. The investigators 
were able to derive a measure of chromosomal instability by measuring “mirrored subclonal 
allelic imbalance”. In simple terms this relies on comparing evolving genomic changes within 
the tumour specimens on the basis of subclonal changes in maternal and paternal alleles. 
The data confirmed that increased levels of chromosomal instability correlated with 
intratumoral heterogeneity as well as increased risk of recurrence or death. These results 
suggest that genomic instability can therefore inform prognosis, and patients at higher risk 
may benefit from more regular follow-up. Measuring circulating tumour DNA in these 
individuals may be particularly advantageous as it may allow diagnosis of relapse or residual 
disease prior to clinically evident metastases [24].  The extent to which these patients would 
benefit from more intensive adjuvant therapy is open to debate. However, based on the 
study described above one could argue that a proportion of these patients will be relatively 
sensitive to anticancer therapy.   
 
Beyond informing clinicians as to which patients require treatment and their likely 
prognosis, our understanding of genomic instability may also guide the choice of 
therapeutic agent. Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors have an established 
role in 1-5% of women with breast cancer who have inherited mutations in BRCA1 or 2. 
However a recent study identified 6 distinct mutational signatures predictive of BRCA 
deficiency which potentially increases the proportion of patients who may benefit from 
PARP1 inhibition to 22% [25]. These findings remain to be validated in clinical cohorts but 
form the basis for tangible and exciting translational clinical trials.  
 
A greater understanding of the interaction of genomic instability and the immune response 
has also led to important clinical observations. Cancer cells deficient in mismatch repair 
acquire a large number of somatic mutations. This can lead to an increase in “non-self” 
immunogenic antigens which renders these cells more sensitive to immune-mediated 
therapies. Accordingly, in a phase 2 study of patients with MMR deficient colorectal (and 
non-colorectal) tumours had significantly better clinical outcomes after treatment with an 
anti–programmed death 1 (PD-1) immune checkpoint inhibitor, pembrolizumab [26]. There 
may, however, be a more complex relationship between mutational load and response to 
immunotherapy. For example, a recent study highlighted that mutations that occur early in 
evolution, and are therefore present in a greater proportion of subclones, improve immune 
recognition, as opposed to mutations that occur late and increase tumour diversity [27]. 
Moreover, aneuploidy has been associated with markers of immune evasion and poor 
clinical responses to immunotherapy [28].  
 
A number of other treatment strategies leveraging the effects of genomic instability are also 
actively being pursued. For instance, aneuploid cells have been shown to be more sensitive 
to agents that increase metabolic stress [29]. Therapies that may reduce tolerance of 
genomic instability, such as reactivation of wildtype p53 function, have also been 
investigated but as yet remain clinically unproven (reviewed in [30]).   
       
But what are the costs of targeting genomic instability in terms of toxicity? The most 
important consideration in this regard relates to the risk of secondary malignancy. One 
might hypothesise that interfering with genomic stability in normal cells might greatly 
increase second cancer risk particularly if DNA repair drugs are used in combination with 
DNA damaging agents. Most of our current data is in patients receiving the PARP inhibitor 
olaparib. There have been initial concerns that the drug might lead to myelodysplastic 
syndrome and therapy-related acute myeloid leukaemia (MDS/t-AML). However, the 
majority of these patients had been heavily pre-treated with platinum agents and were 
therefore already at significant risk of a second cancer. A proportion of olaparib-based 
studies have follow-up data beyond 5 years and pooled data from all studies suggest a 
cumulative incidence for MDS/t-AML of 0.5% [31]. Presently no causative association with 
the drug has been established. The data on newer anti-DDR drugs has yet to mature and 
importantly many cases of second cancers associated with cytotoxic drugs and radiotherapy 
did not emerge until decades after treatment. This is therefore an area that requires close 
monitoring. 
 
To conclude, genomic instability is a key enabler of tumour evolution. In recent years it has 
become clear that its presence contributes to the complexity and heterogeneity of human 
cancer. Moreover, early strategies to leverage genomic instability in order to improve 
clinical outcomes have proved successful. It is likely that as our understanding of the 
phenomenon increases, our opportunities to exploit it will also increase.             
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